Merck Sharp & Dohme Corp. - Recruiting 60 years or older. - A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate.
Amgen - Recruiting 60 years to 90 years. - An Open-label, Randomized, Teriparatide-controlled Study to Evaluate the Effect of Treatment With AMG 785 in Postmenopausal Women With Osteoporosis Previously Treated With Bisphosphonate Therapy.
Amgen - Recruiting 55 years to 90 years. - A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis.
Galapagos NV - Recruiting 18 years or older. - Randomized, Double-blind, Placebo-controlled, Multicenter, Phase IIb Dose Finding Study of GLPG0634 Administered for 24 Weeks in Combination With Methotrexate to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Alone.
Takeda - Recruiting 50 years or older. - A Phase II/III Multicenter, Randomized, Double-blind, Parallel Group Comparative Study to Evaluate the Efficacy and Safety of Oral Administration of NE-58095NF Tablets Versus Once-daily Oral Administration of NE-58095 2.5-mg Tablets for the Treatment of Involutional Osteoporosis.
Medtronic Spinal and Biologics - Recruiting 65 years or older. - A Prospective and Multicenter Evaluation of Outcomes for Quality of Life and Activities of Daily Living for Balloon Kyphoplasty in the Treatment of Vertebral Compression Fractures.
Techfields Pharma Co. Ltd - Recruiting 35 years to 85 years. - A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group, Dose Range Finding Study to Evaluate the Efficacy and Safety of X0002 Spray Versus Placebo in Subjects With Osteoarthritis.
Merck Sharp & Dohme Corp. - Recruiting 12 years to 25 years. - A Single-Dose Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Odanacatib in Adolescents and Young Adults Treated With Glucocorticoids.
Questcor Pharmaceuticals, Inc. - Recruiting 18 years or older. - A Two-part Study Exploring the Efficacy, Safety, and Pharmacodynamics of Acthar in Systemic Lupus Erythematosus Patients With a History of Persistently Active Disease.
Galapagos NV - Recruiting 18 years or older. - Randomized, Double-blind, Placebo-controlled, Multicenter, Phase IIb Dose Finding Study of GLPG0634 Administered for 24 Weeks as Monotherapy to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (MTX) Alone.
National Taiwan University Hospital - Recruiting 18 years to 90 years. - to Compare the Efficacy of Parameters From Different Imaging Modality in Predicting the Risk of Future Vertebral Compression Fracture in Osteoporotic Patients..
Eli Lilly and Company - Recruiting 50 years or older. - Comparison of the Effects of Teriparatide With Those of Risedronate on Lumbar Spine BMD (Bone Mineral Density) in Men and Postmenopausal Women With Low Bone Mass and a Recent Pertrochanteric Hip Fracture.
Teriparatide; Risedronate; Placebo; Calcium; Vitamin D
Novartis - Recruiting 45 years to 85 years. - A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Assess the Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Postmenopausal Women With Low Bone Mineral Density.
Amgen - Recruiting 55 years or older. - A Randomized Double-blind Study to Evaluate the Safety and Efficacy of Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.
GlaxoSmithKline - Recruiting 60 years to 90 years. - A Twelve-Month Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Denosumab in Chinese Postmenopausal Women With Osteoporosis at Increased Risk of Fracture.
Amgen - Recruiting 30 years or older. - A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy.
University of Aarhus - Recruiting 18 years to 70 years. - Long-term Investigation of Resveratrol on Management of Metabolic Syndrome, Osteoporosis and Inflammation, and Identification of Plant Derived Anti-inflammatory Compounds, Study 3.
Ministry of Health & Welfare, Korea - Recruiting 50 years or older. - A Randomized, Single Center, Double Blind, Parallel, Placebo-controlled Clinical Study of Efficacy and Safety of Chung A Won in Women's Patients With Osteoporosis.
Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger)
University of British Columbia - Recruiting 65 years or older. - A Prospective Baseline Assessment of the Risk of Osteoporosis in Patients With Chronic Obstructive Lung Disease and Outcomes After 2 Years; a Pilot Study.
Toowoomba Regional Cancer Research Centre - Recruiting N/A or older. - A Phase 2 Clinical Trial Exploring 3-Dimensional Imaging of Androgen Deprivation Induced Osteoporosis, Radiotherapy Hypofractionation and the Prognostic Significance of Micrometastatic Disease in Men With Prostate Cancer.
Weill Medical College of Cornell University - Recruiting 45 years to 75 years. - A Randomized Placebo Controlled Double Blind Investigation of the Effects of Potassium Citrate on Bone Metabolism in Postmenopausal Osteopenia.
McGill University Health Center - Recruiting 55 years or older. - A Six Month Double-Blind, Placebo-Controlled Trial Followed by Six Month Open-Label Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture..